The Expression And Clinical Significance Of Her-2in The Benign And Malignant Lesions Of Prostate

Objective: Explore the expression of HER-2in he benign and malignant lesions of prostate inXinjiang region and analyze the clinical significance. Provide certain clinical theoretical basisfor the exploration that whether HER-2can be the therapeutic target of the targeted therapy ofprostate cancer or not.Method: Apply the methods of clinical statistics, morphology observation, EnVision immunehistochemical staining and ELISA serological detection to analyze the Her-2gene expressionand the protein content in the serum of65prostate specimens and83blood serum specimens.Selection of the specimens: Choose the prostate tissue specimens which underwent prostatebiopsy, prostate electrocision and prostate Hlsted from January in2010to December in2012from the Urology Surgery in the People’s Hospital in the Xinjiang Uygur Autonomous Region,including40specimens of prostate cancer,20specimens of prostate hyperplasia and5specimens of normal prostate tissues and83serum specimens from the patients with benignand malignant lesions of prostate, among which40are from the patients with prostate cancer,40from patients with prostate hyperplasia and3from healthy males. The cases selected in theexperiment did not receive any drug therapy, physiotherapy or radiotherapy before bloodsampling and other relevant operations such as biopsy, electrocision and curative treatment.Result:1. The results of the Her-2immune histochemical staining of the65prostate tissuespecimensshowed that all the expressions were negative.2. Of the83blood serum specimens,only23cases had Her-2protein content, taking up27.8%. Among the23cases, we coulddetect that there were6cases of prostate hyperplasia in the blood serum samples with Her-2,taking up15%of the hyperplasia group, while there were17cases of prostate cancer,accounting for42.5%of the prostate cancer group. No Her-2content was detected in the3cases of normal blood serum. The Her-2protein content detected from the23cases was:0.62±0.42ng/ml.The Her-2protein content in22cases is lower than1ng/ml and only onepatient’s protein content reaches2.3ng/ml. The results of all the23cases were much lowerthan the positive reference. As for the rest60blood serum specimens, the test failed to detectthe protein content.Conclusion:1. In the Xinjiang region, Her-2has a low expression in the genes of the benignand malignant prostate lesion.2. The Her-2protein content in the benign and malignantprostate patients and the peripheral blood in the healthy people is relatively low.3. Accordingto the experiment results, Her-2can neither be used as the therapeutic target of the prostatecancer, nor can it used as the prognostic factor to appraise prostate cancer.